Analysis of the results of transplantation of the retinal pigment epithelium in the experiment

Abstract

BACKGROUND: A promising method for treating the pathology of the retinal pigment epithelium in age-related macular degeneration is cell replacement therapy.

AIM: The aim of the study was to analyze the results of cell transplantation in the form of a cell suspension into the subretinal space at various times.

MATERIALS AND METHODS: The material of the study was 20 rabbits (40 eyes) of the New Zealand albino breed. A month after the modeling of retinal pigment epithelium atrophy and retinal degeneration, rabbits underwent subretinal transplantation of induced retinal pigment epithelium in the form of a cell suspension. Optical coherence tomography and autofluorescence studies were conducted in a period of up to 8 months. Enucleated eyes of animals were subjected to morphological study.

RESULTS: When observing rabbits with a previously created model of atrophy in the long term, it was found that the cells of the transplanted retinal pigment epithelium remained viable for the entire period. There were no inflammatory reactions from the eyeball, clouding of the optical media, pathological changes in the structure of the retina.

CONCLUSION: Thus, with the introduction of a suspension of induced retinal pigment epithelium cells with atrophy of the retinal pigment epithelium, the injected cells retain their viability for up to 8 months.

Keywords

epithelium / degeneration / transplantation / retina / eyeball / cell therapy

References

[1] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–116. doi: 10.1016/S2214-109X(13)70145-1

[2] Wong W.L., Su X., Li X., et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis // Lancet Glob Health. 2014. Vol. 2, N 2. P. e106–116. doi: 10.1016/S2214-109X(13)70145-1

[3] Cabral de Guimaraes TA, Daich Varela M, Georgiou M, Michaelides M. Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions. Br J Ophthalmol. 2022;106(3):297–304. doi: 10.1136/bjophthalmol-2020-318452

[4] Cabral de Guimaraes T.A., Daich Varela M., Georgiou M., Michaelides M. Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions // Br J Ophthalmol. 2022. Vol. 106, N 3. P. 297–304. doi: 10.1136/bjophthalmol-2020-318452

[5] Duarri A, Rodríguez-Bocanegra E, Martínez-Navarrete G, et al. Transplantation of human induced pluripotent stem cell-derived retinal pigment epithelium in a swine model of geographic atrophy. Int J Mol Sci. 2021;22(19):10497. doi: 10.3390/ijms221910497

[6] Duarri A., Rodríguez-Bocanegra E., Martínez-Navarrete G., et al. Transplantation of human induced pluripotent stem cell-derived retinal pigment epithelium in a swine model of geographic atrophy // Int J Mol Sci 2021. Vol. 22, N 19. P. 10497. doi: 10.3390/ijms221910497

[7] Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908. doi: 10.1056/NEJMoa1102673

[8] Group C.R., Martin D.F., Maguire M.G., et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration // N Engl J Med 2011. Vol. 364, N 20. P. 1897–1908. doi: 10.1056/NEJMoa1102673

[9] Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (vegf trap-eye) in wet agerelated macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi: 10.1016/j.ophtha.2012.09.006

[10] Heier J.S., Brown D.M., Chong V., et al. Intravitreal aflibercept (vegf trap-eye) in wet agerelated macular degeneration // Ophthalmology. 2012. Vol. 119, N 12. P. 2537–2548. doi: 10.1016/j.ophtha.2012.09.006

[11] Sheremet NL, Mikaelyan AA, Andreev AYu, Kiselev SL. Possibilities of treating retinal diseases in patients with damaged retinal pigment epithelium. Vestnik Oftalmologii. 2019;135(5):226–234. (In Russ). doi: 10.17116/oftalma2019135052226

[12] Шеремет Н.Л., Микаелян А.А., Андреев А.Ю., Киселев С.Л. Возможности лечения заболеваний сетчатки, сопровождающихся повреждением ретинального пигментного эпителия // Вестник офтальмологии. 2019. Т. 135. № 5. С. 226–234. doi: 10.17116/oftalma2019135052226

[13] Gayduk KY, Churashov SV, Kulikov AN. Stem cell-based technologies in treatment of age-related macular degeneration patients: current state of the problem. Ophthalmology Reports. 2019;12(4): 35–41. (In Russ). doi: 10.17816/OV12604

[14] Гайдук К.Ю., Чурашов С.В., Куликов А.Н. Клеточные технологии в лечении пациентов с возрастной макулярной дегенерацией: современное состояние проблемы // Офтальмологические ведомости. 2019. Т. 12, № 4. С. 35–41. doi: 10.17816/OV12604

[15] Hacenko EI. Tehnologija podgotovki i transplantacii 3D kletochnyh sferoidov retinal’nogo pigmentnogo jepitelija v jeksperimente [dissertation]. Мoscow, 2019. Available from: https://www.dissercat.com/content/tekhnologiya-podgotovki-i-transplantatsii-3d-kletochnykh-sferoidov-retinalnogo-pigmentnogo (In Russ).

[16] Хаценко Е.И. Технология подготовки и трансплантации 3D клеточных сфероидов ретинального пигментного эпителия в эксперименте: дис. … канд. мед. наук. Москва, 2019. Режим доступа: https://www.dissercat.com/content/tekhnologiya-podgotovki-i-transplantatsii-3d-kletochnykh-sferoidov-retinalnogo-pigmentnogo

[17] Kashani AH. Stem cell therapy in non-neovascular age-related macular degeneration stem cell therapy in non-neovascular AMD. Invest Ophthalmol Vis Sci. 2016;57(5):ORSFm1–ORSFm 9. doi: 10.1167/iovs.15-17681

[18] Kashani A.H. Stem cell therapy in non-neovascular age-related macular degeneration stem cell therapy in non-neovascular AMD // Invest Ophthalmol Vis Sci. 2016. Vol. 57, N 5. P. ORSFm1–ORSFm9. doi: 10.1167/iovs.15-17681

[19] O’Neill HC, Limnios IJ, Barnett NL. Advancing a stem cell therapy for age-related macular degeneration. Curr Stem Cell Res Ther. 2020;15(2):89–97. doi: 10.2174/1574888X15666191218094020

[20] O’Neill H.C., Limnios I.J., Barnett N.L. Advancing a stem cell therapy for age-related macular degeneration // Curr Stem Cell Res Ther. 2020. Vol. 15, N 2. P. 89–97. doi: 10.2174/1574888X15666191218094020

[21] Nazari H, Zhang L, Zhu D, et al. Stem cell based therapies for age-related macular degeneration: the promises and the challenges. Prog Retin Eye Res. 2015;48:1–39. doi: 10.1016/j.preteyeres.2015.06.004

[22] Nazari H., Zhang L., Zhu D., et al. Stem cell based therapies for age-related macular degeneration: the promises and the challenges // Prog Retin Eye Res. 2015. Vol. 48. P. 1–39. doi: 10.1016/j.preteyeres.2015.06.004

[23] Vitillo L, Tovell VE, Coffey P. Treatment of age-related macular degeneration with pluripotent stem cell-derived retinal pigment epithelium. Curr Eye Res. 2020;45(3):361–371. doi: 10.1080/02713683.2019.1691237

[24] Vitillo L., Tovell V.E., Coffey P. Treatment of age-related macular degeneration with pluripotent stem cell-derived retinal pigment epithelium // Current eye research. 2020. Vol. 45, N 3. P. 361–371. doi: 10.1080/02713683.2019.1691237

[25] Humayun MS, Weiland J, Fujii GY, et al. Visual perception in a blind subject with a chronic microelectronic retinal prosthesis. Vis Res. 2003;43(24):2573–2581. doi: 10.1016/s0042-6989(03)00457-7

[26] Humayun M.S., Weiland J., Fujii G.Y., et al. Visual perception in a blind subject with a chronic microelectronic retinal prosthesis // Vis Res. 2003. N 43. P. 2573–2581. doi: 10.1016/s0042-6989(03)00457-7

[27] Maximov VV, Lagarkova MA, Kiselev SL. Gene and cell therapy of retinal diseases. Genes & Cells. 2012;7(3):12–20. (In Russ). doi: 10.23868/gc121564

[28] Максимов В.В., Лагарькова М.А., Киселев С.Л. Генная и клеточная терапия заболеваний сетчатки глаза // Гены и Клетки. 2012. Т. 7, № 3. C. 12–20. doi: 10.23868/gc121564

[29] Borooah S, Phillips M, Bilican B, et al. Using human induced pluripotent stem cells to treat retinal disease. Prog Retin Eye Res. 2013;37:163–181. doi: 10.1016/j.preteyeres.2013.09.002

[30] Borooah S., Phillips M., Bilican B., et al. Using human induced pluripotent stem cells to treat retinal disease // Prog Retin Eye Res. 2013. Vol. 37. P. 163–181. doi: 10.1016/j.preteyeres.2013.09.002

[31] Sheremet NL, Mikaelyan AA, Andreev AYu, Kiselev SL. Possibilities of treating retinal diseases in patients with damaged retinal pigment epithelium. Vestnik Oftalmologii. 2019;135(5):226–234. (In Russ). doi: 10.17116/oftalma2019135052226

[32] Шеремет Н.Л., Микаелян А.А., Андреев А.Ю., Киселев С.Л. Возможности лечения заболеваний сетчатки, сопровождающихся повреждением ретинального пигментного эпителия // Вестник офтальмологии. 2019. Т. 135, № 5. С. 226–234. doi: 10.17116/oftalma2019135052226

[33] Mandai M, Watanabe A, Kurimoto Y, et al. autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017;376(11):1038–1046. doi: 10.1056/NEJMoa1608368

[34] Mandai M., Watanabe A., Kurimoto Y., et al. Autologous induced stem-cell-derived retinal cells for macular degeneration // N Engl J Med. 2017. Vol. 376, N 11. P. 1038–1046. doi: 10.1056/NEJMoa1608368

[35] Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pig-ment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385(9967):509–516. doi: 10.1016/S0140-6736(14)61376-3

[36] Schwartz S.D., Regillo C.D., Lam B.L., et al. Human embryonic stem cell-derived retinal pig-ment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies // Lancet. 2015. Vol. 385, N 9967. P. 509–516. doi: 10.1016/S0140-6736(14)61376-3

[37] Song WK, Park K-M, Kim H-J, et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in asian patients. Stem Cell Rep. 2015;4(5):860–872. doi: 10.1016/j.stemcr.2015.04.005

[38] Song W.K., Park K.-M., Kim H.-J., et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in asian patients // Stem Cell Rep. 2015. Vol. 4, N 5. P. 860–872. doi: 10.1016/j.stemcr.2015.04.005

[39] Falkner-Radler CI, Krebs I, Glittenberg C, et al. Human retinal pigment epithelium (RPE) transplantation: outcome after autologous RPE-choroid sheet and RPE cell-suspension in a randomised clinical study. Br J Ophthalmol. 2011;95(3):370–375. doi: 10.1136/bjo.2009.176305

[40] Falkner-Radler C.I., Krebs I., Glittenberg C., et al. Human retinal pigment epithelium (RPE) transplantation: outcome after autologous RPE-choroid sheet and RPE cell-suspension in a randomised clinical study // Br J Ophthalmol. 2011. Vol. 95, N 3. P. 370–375. doi: 10.1136/bjo.2009.176305

[41] Mehat MS, Sundaram V, Ripamonti C, et al. Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration. Ophthalmology. 2018;125(11):1765–1775. doi: 10.1016/j.ophtha.2018.04.037

[42] Mehat M.S., Sundaram V., Ripamonti C., et al. Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration // Ophthalmology. 2018. Vol. 125, N 11. P. 1765–1775. doi: 10.1016/j.ophtha.2018.04.037

[43] Schwartz SD, Hubschman J-P, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379(9817):713–720. doi: 10.1016/S0140-6736(12)60028-2

[44] Schwartz S.D., Hubschman J.-P., Heilwell G., et al. Embryonic stem cell trials for macular degeneration: a preliminary report // Lancet. 2012. Vol. 379, N 9817. P. 713–720. doi: 10.1016/S0140-6736(12)60028-2

[45] Diniz B, Thomas P, Thomas B, et al. Subretinal implantation of retinal pigment epithelial cells derived from human embryonic stem cells: improved survival when implanted as a monolayer. Invest Ophthalmol Vis Sci. 2013;54(7):5087–5096. doi: 10.1167/iovs.12-11239

[46] Diniz B., Thomas P., Thomas B., et al. Subretinal implantation of retinal pigment epithelial cells derived from human embryonic stem cells: improved survival when implanted as a monolayer // Invest Ophthalmol Vis Sci. 2013. Vol. 54, N 7. P. 5087–5096. doi: 10.1167/iovs.12-11239

[47] Koster C, Wever KE, Wagstaff PE, et al. A systematic review on transplantation studies of the retinal pigment epithelium in animal models. Int J Mol Sci. 2020;21(8):2719. doi: 10.3390/ijms21082719

[48] Koster C., Wever K.E., Wagstaff P.E., et al. A systematic review on transplantation studies of the retinal pigment epithelium in animal models // Int J Mol Sci. 2020. Vol. 21, N 8. P. 2719. doi: 10.3390/ijms21082719

[49] Patent RUS N 2709247/17.12.2019. Neroev VV, Katargina LA, Neroeva NV, et al. Sposob modelirovanija atrofii retinal’nogo pigmentnogo jepitelija. Available from: https://eyepress.ru/article.aspx?42226 (In Russ).

[50] Патент РФ № 2709247/17.12.2019. Нероев В.В., Катаргина Л.А., Нероева Н.В., и др. Способ моделирования атрофии ретинального пигментного эпителия. Режим доступа: https://eyepress.ru/article.aspx?42226 Дата обращения: 21.01.2023.

[51] Neroeva NV, Neroev VV, Katargina LA, et al. Experimental stem cell replacement transplantation in retinal pigment epithelium atrophy. Vestnik Oftalmologii. 2022;138(3):7–15. (In Russ). doi: 10.17116/oftalma20221380317

[52] Нероева Н.В., Нероев В.В., Катаргина Л.А., и др. Заместительная трансплантация стволовыми клетками при атрофии ретинального пигментного эпителия в эксперименте // Вестник офтальмологии. 2022. Т. 138, № 3. С. 7–15. doi: 10.17116/oftalma20221380317

[53] Patent RUS N 2729937/13.08.2020. Bjul. N 23. Neroeva NV, Neroev VV, Katargina LA, et al. Sposob subretinal’noj transplantacii kletok retinal’nogo pigmentnogo jepitelija (RPJe), differencirovannyh iz inducirovannyh pljuripotentnyh stvolovyh kletok cheloveka pri atrofii retinal’nogo pigmentnogo jepitelija v jeksperimente. Available from: https://www.mediasphera.ru/issues/vestnik-oftalmologii/2022/3/10042465X2022031007 (In Russ).

[54] Патент РФ на изобретение № 2729937/13.08.2020. Бюл. № 23. Нероева Н.В., Нероев В.В., Катаргина Л.А., и др. Способ субретинальной трансплантации клеток ретинального пигментного эпителия (РПЭ), дифференцированных из индуцированных плюрипотентных стволовых клеток человека при атрофии ретинального пигментного эпителия в эксперименте. Режим доступа: https://www.mediasphera.ru/issues/vestnik-oftalmologii/2022/3/10042465X2022031007 Дата обращения: 21.01.2023.

RIGHTS & PERMISSIONS

Eco-Vector